Docoh
Loading...

RSPI RespireRx Pharmaceuticals

Cannabinoids is a broad term to describe the pharmacologically active naturally occurring substances found within the cannabis (marijuana) plant. While the liberalization of state laws regulating the use and sales of marijuana has created a major industry based on the commercialization of marijuana for both medical and recreational use, the U.S. Food and Drug Administration (“FDA”) has not recognized or approved the marijuana plant as medicine nor is it federally legal to sell products that contain cannabinoids as drugs, dietary supplements or foods (edibles) without its approval. From a scientific and pharmaceutical perspective, however, we do not think that pharmaceutical cannabinoids should suffer from the stigma that marijuana has, since it was declared a controlled substance in the 1930’s. We believe that cannabinoids should be considered pharmaceuticals developed under FDA and comparable international regulatory bodies that happen to have been originally derived from plants much like aspirin, theophylline or tamoxifen.

Company profile

Ticker
RSPI, RSPID
Exchange
CEO
Arnold S. Lippa
Employees
Incorporated
Location
Fiscal year end
Former names
CORTEX PHARMACEUTICALS INC/DE/
SEC CIK
IRS number
330303583

RSPI stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

31 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 216 216 216 216 216 216
Cash burn (monthly) 425.33 (positive/no burn) 437.33K 239.99K 81.43K 33.18K
Cash used (since last report) 2.76K n/a 2.84M 1.56M 528.15K 215.2K
Cash remaining -2.54K n/a -2.84M -1.56M -527.94K -214.99K
Runway (months of cash) -6.0 n/a -6.5 -6.5 -6.5 -6.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Sep 20 Jeff Eliot Margolis Common Stock Conversion Aquire C Yes No 0 5,017,144 0 5,142,351
30 Sep 20 Jeff Eliot Margolis Common Stock Conversion Aquire C Yes No 0 5,017,144 0 5,142,351
30 Sep 20 Jeff Eliot Margolis Common Stock Conversion Aquire C Yes No 0 91,871,094 0 96,151,863
30 Sep 20 Jeff Eliot Margolis Warrants (to purchase Common Stock) Common Stock Conversion Aquire C Yes No 0.007 5,017,144 35.12K 5,017,144
30 Sep 20 Jeff Eliot Margolis Warrants (to purchase Common Stock) Common Stock Conversion Aquire C Yes No 0.007 5,017,144 35.12K 5,017,144
30 Sep 20 Jeff Eliot Margolis Warrants (to purchase Common Stock) Common Stock Conversion Aquire C Yes No 0.007 91,871,094 643.1K 91,871,094
30 Sep 20 Jeff Eliot Margolis Series H Preferred Stock Conversion Units Gift Aquire G Yes No 0.0064 7 0.04 32.11
30 Sep 20 Jeff Eliot Margolis Series H Preferred Stock Conversion Units Gift Dispose G No No 0.0064 7 0.04 0
30 Sep 20 Jeff Eliot Margolis Series H Preferred Stock Conversion Units Gift Aquire G Yes No 0.0064 7 0.04 32.11
30 Sep 20 Jeff Eliot Margolis Series H Preferred Stock Conversion Units Gift Dispose G No No 0.0064 7 0.04 7

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • The Company’s unaudited consolidated statements of operations as discussed herein are presented below.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absorb, ADME, Alexa, amnesia, ascending, Attorney, auxiliary, began, behalf, bench, beneficiary, biotechnology, bona, book, broaden, broadly, brought, buy, calendar, candidate, caution, cautionary, certainty, chain, choose, civil, CMC, coined, commensurate, compete, confidence, consumer, consuming, contemplated, correct, correspondingly, cure, customer, Dawn, deadline, deal, decline, delisted, deposit, deposited, designee, desist, Dickason, difficulty, diminished, director, discourage, dispose, disposing, disproportionately, divert, dividend, downgrade, downturn, duty, economy, Emily, encounter, endocannabinoid, environment, exacerbated, excretion, exert, exerting, expend, expended, expenditure, fail, fall, fide, fiduciary, figure, FINRA, Fire, fluctuate, foreseeable, fruition, furnish, GABAAsubtype, governance, governing, government, great, growing, grown, GW, hard, healthcare, heightening, hurt, illustrated, impede, implied, impose, imposed, improper, inability, inaccurate, inefficiency, influence, infrastructure, instrument, intangible, intensify, interfering, invoicing, issuer, knowledge, line, litigation, local, located, lose, loyalty, Manhattan, Matthew, mind, misconduct, modify, momentum, monetary, Nabiximol, neuropathy, newly, nominating, oromucosal, OTC, oversight, oxygen, pattern, PD, penny, Pharma, pharmacodynamic, pilot, Pink, PK, plc, precipitously, Preclincial, prevailing, professional, profitability, prohibit, prosecution, proxy, purity, quotation, rail, rare, recommend, recommended, recommending, recruit, recruiting, reissued, remediate, repurposing, resale, Respire, reverse, risky, screening, seasoned, sentiment, settle, Shane, shortest, speculative, spend, spending, split, sporadically, spouse, spray, spread, steady, strain, successor, suitable, surviving, tandem, tangible, temporary, terminology, THC, thinly, tier, timeframe, titled, tradename, transitional, transparent, trust, trustee, typically, unavailable, undue, uneconomical, unemployment, unenforced, unexpected, unknown, unpredictable, unsafe, upfront, venture, view, viewed, vii, violation, virtually, vitro, voluntarily, webcast, Wisconsin
Removed: aberrant, abnormal, adherence, adulthood, Advancement, affecting, aged, aggression, agonistic, Alberta, allele, amelioration, anesthetic, announce, antagonist, antagonistic, aripiprazole, ASD, attended, autism, autistic, behavioral, biomarker, blind, branded, categorized, CDC, clarified, climate, Clustered, collapsing, comprising, configuration, connectivity, consumption, core, counsel, CRISPR, CSA, curative, desensitization, Diego, disordered, dispute, disputed, disrupted, dominant, double, dramatic, dysfunction, editing, Edmonton, educational, elusive, emotional, environmental, etiologic, etiology, evidenced, expanded, expansion, explore, extreme, facilitation, Fragile, FXS, gene, generation, genome, glutamatergic, granting, guard, healthy, identifiable, inclusion, infection, instability, interpersonal, Interspaced, introduced, invoked, irritability, jaw, language, largest, light, LTF, MAD, malfunction, Mandibular, mask, mechanical, medicinal, modulate, molecular, mood, mutation, naloxone, naturally, negotiate, neurodevelopmental, opening, output, Palindromic, persist, person, phenotype, physical, physiological, play, political, population, positively, prescription, prevalence, prevention, pullback, purported, ranging, reallocate, rebuilding, remained, representation, retained, Retaining, risen, risperidone, San, sense, sequence, sequencing, showed, signal, slightly, smell, spectrum, splint, Stargazin, stimulating, stimuli, studied, studying, subtle, surgically, synapse, syndrome, TEC, teenage, tentatively, thought, Today, trafficking, transmembrane, transmitter, TRD, UCSD, understand, uvulopalatopharyngoplasty, valuable, verbal, voice